DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.
[en] The E2F transcription factor 1 is subtly regulated along the cell cycle progression and in response to DNA damage by post-translational modifications. Here, we demonstrated that the E3-ubiquitin ligase cellular inhibitor of apoptosis 1 (cIAP1) increases E2F1 K63-poly-ubiquitination on the lysine residue 161/164 cluster, which is associated with the transcriptional factor stability and activity. Mutation of these lysine residues completely abrogates the binding of E2F1 to CCNE, TP73 and APAF1 promoters, thus inhibiting transcriptional activation of these genes and E2F1-mediated cell proliferation control. Importantly, E2F1 stabilization in response to etoposide-induced DNA damage or during the S phase of cell cycle, as revealed by cyclin A silencing, is associated with K63-poly-ubiquitinylation of E2F1 on lysine 161/164 residues and involves cIAP1. Our results reveal an additional level of regulation of the stability and the activity of E2F1 by a non-degradative K63-poly-ubiquitination and uncover a novel function for the E3-ubiquitin ligase cIAP1.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Glorian, Valérie; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
Allègre, Jennifer; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
Berthelet, Jean; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
Dumetier, Baptiste; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
Boutanquoi, Pierre-Marie; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
Droin, Nathalie; Inserm U1170, Gustave Roussy, Villejuif, France.
Kayaci, Cémile; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
Cartier, Jessy; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
Gemble, Simon; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
Marcion, Guillaume ; Université de Liège - ULiège > GIGA > GIGA I3 - Hematology ; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
Gonzalez, Daniel; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231, ; Centre Georges-François Leclerc, Dijon, France.
Boidot, Romain; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231, ; Centre Georges-François Leclerc, Dijon, France.
Garrido, Carmen; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
Michaud, Olivier; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
Solary, Eric; Inserm U1170, Gustave Roussy, Villejuif, France. ; Université Paris-Sud, Faculté de Médecine, Le Kremlin Bicêtre, France.
Dubrez, Laurence; Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France. ; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231,
DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.
Laine A, Westermarck J. Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells. Clin Cancer Res 2014; 20: 3644–3650.
Munro S, Carr SM, La Thangue NB. Diversity within the pRb pathway: is there a code of conduct? Oncogene 2012; 31: 4343–4352.
Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol 2013; 14: 518–528.
Biswas AK, Johnson DG. Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res 2012; 72: 13–17.
Erpapazoglou Z, Walker O, Haguenauer-Tsapis R. Versatile roles of k63-linked ubiquitin chains in trafficking. Cells 2014; 3: 1027–1088.
Marti A, Wirbelauer C, Scheffner M, Krek W. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1999; 1: 14–19.
Peart MJ, Poyurovsky MV, Kass EM, Urist M, Verschuren EW, Summers MK et al. APC/C (Cdc20) targets E2F1 for degradation in prometaphase. Cell Cycle 2010; 9: 3956–3964.
Budhavarapu VN, White ED, Mahanic CS, Chen L, Lin FT, Lin WC. Regulation of E2F1 by APC/C Cdh1 via K11 linkage-specific ubiquitin chain formation. Cell Cycle 2012; 11: 2030–2038.
Mahanic CS, Budhavarapu V, Graves JD, Li G, Lin WC. Regulation of E2 promoter binding factor 1 (E2F1) transcriptional activity through a deubiquitinating enzyme, UCH37. J Biol Chem 2015; 290: 26508–26522.
Wang B, Ma A, Zhang L, Jin WL, Qian Y, Xu G et al. POH1 deubiquitylates and stabilizes E2F1 to promote tumour formation. Nat Commun 2015; 6: 8704.
Estornes Y, Bertrand MJ. IAPs, regulators of innate immunity and inflammation. Semin Cell Dev Biol 2014; 39: 106–114.
Cartier J, Berthelet J, Marivin A, Gemble S, Edmond V, Plenchette S et al. Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription. J Biol Chem 2011; 286: 26406–26417.
Che X, Yang D, Zong H, Wang J, Li X, Chen F et al. Nuclear cIAP1 overexpression is a tumor stage-and grade-independent predictor of poor prognosis in human bladder cancer patients. Urol Oncol 2012; 30: 450–456.
Plenchette S, Cathelin S, Rebe C, Launay S, Ladoire S, Sordet O et al. Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event. Blood 2004; 104: 2035–2043.
Tanimoto T, Tsuda H, Imazeki N, Ohno Y, Imoto I, Inazawa J et al. Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas. Cancer Lett 2005; 224: 141–151.
Feltham R, Bettjeman B, Budhidarmo R, Mace PD, Shirley S, Condon SM et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. J Biol Chem 2011; 286: 17015–17028.
Marzio G, Wagener C, Gutierrez MI, Cartwright P, Helin K, Giacca M. E2F family members are differentially regulated by reversible acetylation. J Biol Chem 2000; 275: 10887–10892.
Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem 2012; 55: 4101–4113.
Zheng S, Moehlenbrink J, Lu YC, Zalmas LP, Sagum CA, Carr S et al. Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1. Mol Cell 2013; 52: 37–51.
Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J et al. Arginine methylation controls growth regulation by E2F-1. EMBO J 2012; 31: 1785–1797.
Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 2001; 15: 1833–1844.
Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 2003; 5: 401–409.
Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 2003; 5: 552–558.
Ianari A, Gallo R, Palma M, Alesse E, Gulino A. Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J Biol Chem 2004; 279: 30830–30835.
Aoki I, Higuchi M, Gotoh Y. NEDDylation controls the target specificity of E2F1 and apoptosis induction. Oncogene 2013; 32: 3954–3964.
Galbiati L, Mendoza-Maldonado R, Gutierrez MI, Giacca M. Regulation of E2F-1 after DNA damage by p300-mediated acetylation and ubiquitination. Cell Cycle 2005; 4: 930–939.
Nakatani Y, Kleffmann T, Linke K, Condon SM, Hinds MG, Day CL. Regulation of ubiquitin transfer by XIAP, a dimeric RING E3 ligase. Biochem J 2013; 450: 629–638.
Feltham R, Moulin M, Vince JE, Mace PD, Wong WW, Anderton H et al. Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding. J Biol Chem 2010; 285: 17525–17536.
Dynek JN, Goncharov T, Dueber EC, Fedorova AV, Izrael-Tomasevic A, Phu L et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J 2010; 29: 4198–4209.
Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008; 283: 24295–24299.
Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689–700.
de Almagro MC, Goncharov T, Newton K, Vucic D. Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination. Cell Death Dis 2015; 6: e1800.
Xu L, Zhu J, Hu X, Zhu H, Kim HT, LaBaer J et al. c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1. Mol Cell 2007; 28: 914–922.
Qi Y, Xia P. Cellular inhibitor of apoptosis protein-1 (cIAP1) plays a critical role in beta-cell survival under endoplasmic reticulum stress: promoting ubiquitination and degradation of C/EBP homologous protein (CHOP). J Biol Chem 2012; 287: 32236–32245.
Hanson AJ, Wallace HA, Freeman TJ, Beauchamp RD, Lee LA, Lee E. XIAP monoubiquitylates Groucho/TLE to promote canonical Wnt signaling. Mol Cell 2012; 45: 619–628.
Harikumar KB, Yester JW, Surace MJ, Oyeniran C, Price MM, Huang WC et al. K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5. Nat Immunol 2014; 15: 231–238.
Loftus SJ, Liu G, Carr SM, Munro S, La Thangue NB. NEDDylation regulates E2F-1-dependent transcription. EMBO Rep 2012; 13: 811–818.
Rahighi S, Dikic I. Selectivity of the ubiquitin-binding modules. FEBS Lett 2012; 586: 2705–2710.
Marivin A, Berthelet J, Cartier J, Paul C, Gemble S, Morizot A et al. cIAP1 regulates TNF-mediated cdc42 activation and filopodia formation. Oncogene 2014; 33: 5534–5545.
